Vaccines Market Outlook

The vaccines market is likely to strengthen its boundaries at an average CAGR of 6.6% during the forecast period. The market is expected to hold a value of US$ 42.7 billion in 2023 while it is anticipated to cross a value of US$ 80.8 billion by 2033.

The research report on the vaccines market explains that the Covid-19 spread turning into a full-fledged pandemic has fueled the demand for vaccines. Furthermore, governments investing huge capital in progressive healthcare systems are anticipated to expand the vaccine market size. Government healthcare programs deliver vaccines to infants to provide them with prevention from chronic diseases like tuberculosis, rotavirus, etc. The rise in new diseases like H1B1 infection, and swine flu (H1N1) is pushing the authorities to adopt new methods that help in preventing the diseases.

The vaccines market outlook states that the rising incidence of diseases worldwide is encouraging the adoption of vaccines, thereby creating prospects for the growth of the vaccines market. Deadly diseases such as tuberculosis, cancer, influenza, and pneumonia have high fatality rates, which is compelling people to opt for vaccinations. For instance, as per the World Health Organization (WHO), around 1.5 million people died from tuberculosis in 2020 while over 10 million people fell ill with TB. Additionally, increasing public awareness about the benefits of vaccination along with rising government support in research and development is likely to act as a catalyst for the growth of the vaccines market.

Attributes Details
Vaccines Market CAGR (2023 to 2033) 6.6%
Vaccines Market Size (2023) US$ 42.7 billion
Vaccines Market Size (2033) US$ 80.8 billion

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

How is the Future Outlook (2023 to 2033)  for the Vaccines Market in Comparison to the Historical Pattern (2017 to 2022)

Short-term Growth: Factors such as the rising prevalence of chronic and infectious diseases, increase in immunization programs, advancements in vaccine technology, and changing attitudes towards vaccines are some of the key factors expected to drive the growth in the vaccines market during the forecast period.

Since their invention, vaccines have completely revolutionized the healthcare industry across the world. They have become ideal healthcare preventive products used for enhancing immunity against numerous diseases. Expansion of the prevention vaccines market and growing awareness among people in developing regions about the benefits of vaccines is likely to boost the vaccines market growth.

Mid-term Growth: The rising need for protecting children from deadly chronic and infectious diseases like tuberculosis, cancer, hepatitis, influence, etc. is expected to create lucrative opportunities for vaccine manufacturers during the forecast period. According to the United Nations Children’s Fund (UNICEF), each year vaccination saves 2 to 3 million children from deadly diseases.

Vaccine manufacturing giants like Pfizer and GSK are vigorously investing in vaccine research and development for introducing new products with a highly effective nature. Besides this, they are holding various trials for establishing the safety and efficacy of vaccines. For instance, in January 2022, Pfizer Inc., and BioNTech SE initiated a clinical study to evaluate the safety, immunogenicity, and tolerability of an Omicron-based vaccine candidate in adults aged 18 to 55. The market is anticipated to thrive at a significant CAGR between 2022 and 2028.

Long-term Growth: Rapidly evolving technology has a profound impact on vaccine market trends. Developments like the introduction of genetic engineering and lab automation are helping vaccine manufacturers to develop low-cost vaccines, which may attract markets and eventually enable vaccine market access.

Additionally, various initiatives taken by governments of emerging nations for launching mass vaccination drives may augment the overall vaccines industry worth in the future. Global vaccine demand is anticipated to rise at 6.6% CAGR during the forecast period from 2023 and 2033.

Which Factors Are Challenging the Vaccine Market Growth?

High Capital Investments and Low Purchasing Power in Emerging Markets May Impede Market Development.

The development of vaccines is a lengthy, complicated, and expensive process. As a result, most of the vaccines are usually costlier, which is acting as a key hurdle in the growth of the vaccines market. Similarly, lack of awareness and poor healthcare infrastructure across developing regions have also hampered vaccine market access.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Vaccines Market Country-wise Insights

Regions Absolute Market Growth
United States US$ 14.8 billion
United Kingdom  US$ 1.5 billion
China  US$ 3.5 billion
Japan  US$ 2.3 billion
India US$ 1.3 billion

Which Region leads the Market in terms of Market Share?

Higher Healthcare Budget post Pandemic along with the Presence of Vaccine Giants propels the Regional Growth

United States Market CAGR (2023 to 2033) 6.6%
United States Market Absolute Doller Growth (US$ million/billion) US$ 14.8 billion

The United States is the leading market for vaccines in 2023 and is forecast to grow at a prolific CAGR over the forecast period, owing to the presence of leading vaccine manufacturers, increasing investments in research and development, continuous vaccine launches and approvals, availability of highly advanced technologies, awareness among people about latest vaccines market trends, and expansion of veterinary vaccines market. The United States market is expected to thrive at a CAGR of 6.6% between 2023 and 2033.

Similarly, the rising incidence of infectious and chronic diseases in the country has become a crucial factor in boosting vaccine market growth. According to the Centers for Disease Control and Prevention (CDC), around 6,400,000 to 11,000,000 flu illnesses cases were recorded between October 1, 2021, through May 7, 2022, in the United States.

People in the United States are spending large amounts on vaccines to make themselves immune to various diseases. Thus, growing concerns about rising cases of various infectious diseases and positive attitudes toward vaccines may significantly increase the vaccine industry worth in the future.

Furthermore, increasing government initiatives coupled with the expansion of the COVID-19 vaccine market size are expected to boost the growth of the vaccine market in the United States during the forthcoming period. The market is anticipated to reach a value of US$ 31.4 billion by 2033.

What makes China a Leading Vaccines Market in terms of CAGR?

Changing Attitudes Towards Vaccines and Favorable Government Support Creating Space for Vaccine Market Growth in China

Region Attributes
Chinese Market CAGR (2023 to 2033) 8.9%
Chinese Market Absolute Doller Growth (US$ million/billion) US$ 3.5 billion

As per FMI, the vaccines market in China is poised to exhibit strong on the back of increasing government spending for immunization programs, changing attitudes of people towards vaccinations, rise in the development of novel vaccines, the emergence of new vaccine market trends, the surge in various diseases, and expansion of meningococcal vaccines market in the country. The Chinese market is likely to expand at a CAGR of 8.9% between 2023 and 2033 while it is expected to cross a value of US$ 6.0 billion by 2033.

Furthermore, the rapidly growing population and rising health awareness among people in the country are making a conducive environment for the growth of the vaccine market.

Demand for vaccines was especially high during the COVID-19 pandemic and it is expected to continue at a steady pace during the post-pandemic period as people's attitude towards vaccines takes a positive turn.

Category-wise Insights

Segment Top Vaccine Type
Top Sub-segment Subunit & Conjugate
CAGR (2017 to 2022) 5.8%
CAGR (2023 to 2033) 7.3%
Segment Route of Administration
Top Sub-segment Injectable
CAGR (2017 to 2022) 6.0%
CAGR (2023 to 2033) 6.7%

Highly Applicable for Infants, Conjugate Vaccines work on the Antigen Hiding Prospects

As per FMI, the conjugate vaccines segment accounted for the leading share of the global vaccine market by vaccine type due to increased spending by government and private companies on its development. Rising preference for conjugate vaccines is due to their various additional features including greater antibody persistence and avidity. The segment is likely to thrive at a CAGR of 7.3% between 2023 and 2033.

Growing demand for conjugate vaccines due to their ability to provide long-lasting immunity against diseases may continue to offer lucrative opportunities to vaccine manufacturers during the forecast period, thereby boosting vaccines market growth

Effective, Faster, and Efficient Route of Administration Drive Injectable Type Vaccines

Based on the route of administration, injectable (intramuscular and subcutaneous) routes are the most preferred methods used by medical professionals globally. These routes are especially ideal when larger volumes of drugs are to be administrated into the body.

Administration of drugs through the intramuscular route offers various benefits which include rapid absorption and less pain. The segment thrives at a CAGR of 6.7% between 2023 and 2033.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Competition Scenario

Leading players are continuously investing in research and development activities for introducing novel vaccines with long-term efficacy. Besides this, they are adopting growth strategies such as new product launches and approvals, partnerships, acquisitions, and strengthening of distribution channels to expand their global footprint.

Recent Market Developments

  • In 2021, MSD Pharmaceuticals, a wholly-owned subsidiary of Merck Sharp & Dohme, launched Gardasil 9, India’s first gender-neutral HPV vaccine.
  • In April 2020, the United States Food and Drug Administration (FDA), approved Sanofi’s MenQuadfi vaccine for the prevention of invasive meningococcal diseases in persons aged 2 years and older.
  • In 2021, Abbott launched a new inactivated quadrivalent vaccine for influenza in India that offers protection against four virus strains, in India.

Key Contributors to the Vaccines Market

  • Merck & Co., Inc
  • GlaxoSmithKline
  • Pfizer BioNTech
  • Sanofi SA
  • CSL Limited
  • Emergent Biosolutions Inc.
  • Johnson & Johnson (J&J)
  • AstraZeneca plc
  • Bavarian Nordic A/S
  • Mitsubishi Tanabe Pharma Corporation.
  • Out of these GSK
  • Pfizer
  • Mark
  • Sanofi

Key Segments

By Vaccine Type:

  • Inactivated
  • Live attenuated
  • Recombinant
  • Toxoid
  • Subunit & Conjugate

By Valance:

  • Monovalent
  • Multivalent

By Route of Administration:

  • Injectable
  • Oral

By Indication:

  • Influenza
  • Pneumococcal Diseases
  • Human Papillomavirus
  • Meningococcal Diseases
  • Rotavirus
  • MMR
  • Hepatitis
  • DTP
  • Polio

By Distribution Channel:

  • Hospital Pharmacies
  • Institutional Sales
  • Retail Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific (APAC)
  • The Middle East & Africa (MEA)

Frequently Asked Questions

How Big is the Vaccines Market?

The vaccines market is expected to reach US$ 42.7 billion in 2023.

What is the Anticipated CAGR of the Market?

The market is anticipated to expand at a CAGR of 6.6%.

Which Trends are Yielding Market Expansion?

The emergence of gene-based vaccines in addition to immunotherapy and immunization.

Which Opportunities are Yielding Market Expansion?

The advent of RNA and DNA-based vaccines are yielding significant opportunities.

What is the Market CAGR of China Market?

The China market is expected to expand at a CAGR of 8.9% through 2033.

Table of Content
1. Executive Summary | Vaccines Market
    1.1. Global Market Outlook
    1.2. Demand-side Trends
    1.3. Supply-side Trends
    1.4. Technology Roadmap Analysis
    1.5. Analysis and Recommendations
2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
3. Market Background
    3.1. Market Dynamics
        3.1.1. Drivers
        3.1.2. Restraints
        3.1.3. Opportunity
        3.1.4. Trends
    3.2. Scenario Forecast
        3.2.1. Demand in Optimistic Scenario
        3.2.2. Demand in Likely Scenario
        3.2.3. Demand in Conservative Scenario
    3.3. Opportunity Map Analysis
    3.4. Investment Feasibility Matrix
    3.5. PESTLE and Porter’s Analysis
    3.6. Regulatory Landscape
        3.6.1. By Key Regions
        3.6.2. By Key Countries
    3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033
    4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2022
    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
        4.2.1. Y-o-Y Growth Trend Analysis
        4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Vaccine Type
    5.1. Introduction / Key Findings
    5.2. Historical Market Size Value (US$ Million) Analysis By Vaccine Type, 2017 to 2022
    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Vaccine Type, 2023 to 2033
        5.3.1. Inactivated
        5.3.2. Live Attenuated
        5.3.3. Toxoid
        5.3.4. Subunit & Conjugate
        5.3.5. Others
    5.4. Y-o-Y Growth Trend Analysis By Vaccine Type, 2017 to 2022
    5.5. Absolute $ Opportunity Analysis By Vaccine Type, 2023 to 2033
6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Valance
    6.1. Introduction / Key Findings
    6.2. Historical Market Size Value (US$ Million) Analysis By Valance, 2017 to 2022
    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Valance, 2023 to 2033
        6.3.1. Monovalent
        6.3.2. Multivalent
    6.4. Y-o-Y Growth Trend Analysis By Valance, 2017 to 2022
    6.5. Absolute $ Opportunity Analysis By Valance, 2023 to 2033
7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication
    7.1. Introduction / Key Findings
    7.2. Historical Market Size Value (US$ Million) Analysis By Indication , 2017 to 2022
    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication , 2023 to 2033
        7.3.1. DTP
        7.3.2. Hepatitis
        7.3.3. Human Papillomavirus
        7.3.4. Influenza
        7.3.5. Meningococcal Disease
        7.3.6. MMR
        7.3.7. Pneumococcal Disease
        7.3.8. Polio
        7.3.9. Rotavirus
        7.3.10. Others
    7.4. Y-o-Y Growth Trend Analysis By Indication , 2017 to 2022
    7.5. Absolute $ Opportunity Analysis By Indication , 2023 to 2033
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration
    8.1. Introduction / Key Findings
    8.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2017 to 2022
    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
        8.3.1. Injectable
            8.3.1.1. Intramuscular
            8.3.1.2. Subcutaneous
        8.3.2. Oral
        8.3.3. Others
    8.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017 to 2022
    8.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
    9.1. Introduction / Key Findings
    9.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2017 to 2022
    9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
        9.3.1. Hospital Pharmacies
        9.3.2. Institutional Sales
        9.3.3. Retail Pharmacies
    9.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017 to 2022
    9.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
    10.1. Introduction
    10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2022
    10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
        10.3.1. North America
        10.3.2. Latin America
        10.3.3. Europe
        10.3.4. Asia Pacific
        10.3.5. Middle East and Africa
    10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        11.2.1. By Country
            11.2.1.1. The USA
            11.2.1.2. Canada
        11.2.2. By Vaccine Type
        11.2.3. By Valance
        11.2.4. By Indication
        11.2.5. By Route of Administration
        11.2.6. By Distribution Channel
    11.3. Market Attractiveness Analysis
        11.3.1. By Country
        11.3.2. By Vaccine Type
        11.3.3. By Valance
        11.3.4. By Indication
        11.3.5. By Route of Administration
        11.3.6. By Distribution Channel
    11.4. Key Takeaways
12. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        12.2.1. By Country
            12.2.1.1. Brazil
            12.2.1.2. Mexico
            12.2.1.3. Rest of Latin America
        12.2.2. By Vaccine Type
        12.2.3. By Valance
        12.2.4. By Indication
        12.2.5. By Route of Administration
        12.2.6. By Distribution Channel
    12.3. Market Attractiveness Analysis
        12.3.1. By Country
        12.3.2. By Vaccine Type
        12.3.3. By Valance
        12.3.4. By Indication
        12.3.5. By Route of Administration
        12.3.6. By Distribution Channel
    12.4. Key Takeaways
13. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        13.2.1. By Country
            13.2.1.1. Germany
            13.2.1.2. United Kingdom (UK)
            13.2.1.3. France
            13.2.1.4. Spain
            13.2.1.5. Italy
            13.2.1.6. Rest of Europe
        13.2.2. By Vaccine Type
        13.2.3. By Valance
        13.2.4. By Indication
        13.2.5. By Route of Administration
        13.2.6. By Distribution Channel
    13.3. Market Attractiveness Analysis
        13.3.1. By Country
        13.3.2. By Vaccine Type
        13.3.3. By Valance
        13.3.4. By Indication
        13.3.5. By Route of Administration
        13.3.6. By Distribution Channel
    13.4. Key Takeaways
14. Asia Pacific Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        14.2.1. By Country
            14.2.1.1. China
            14.2.1.2. India
            14.2.1.3. Thailand
            14.2.1.4. Singapore
            14.2.1.5. Australia
            14.2.1.6. Rest of Asia Pacific
        14.2.2. By Vaccine Type
        14.2.3. By Valance
        14.2.4. By Indication
        14.2.5. By Route of Administration
        14.2.6. By Distribution Channel
    14.3. Market Attractiveness Analysis
        14.3.1. By Country
        14.3.2. By Vaccine Type
        14.3.3. By Valance
        14.3.4. By Indication
        14.3.5. By Route of Administration
        14.3.6. By Distribution Channel
    14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        15.2.1. By Country
            15.2.1.1. GCC Countries
            15.2.1.2. South Africa
            15.2.1.3. Israel
            15.2.1.4. Rest of Middle East and Africa
        15.2.2. By Vaccine Type
        15.2.3. By Valance
        15.2.4. By Indication
        15.2.5. By Route of Administration
        15.2.6. By Distribution Channel
    15.3. Market Attractiveness Analysis
        15.3.1. By Country
        15.3.2. By Vaccine Type
        15.3.3. By Valance
        15.3.4. By Indication
        15.3.5. By Route of Administration
        15.3.6. By Distribution Channel
    15.4. Key Takeaways
16. Key Countries Market Analysis
    16.1. USA
        16.1.1. Pricing Analysis
        16.1.2. Market Share Analysis, 2022
            16.1.2.1. By Vaccine Type
            16.1.2.2. By Valance
            16.1.2.3. By Indication
            16.1.2.4. By Route of Administration
            16.1.2.5. By Distribution Channel
    16.2. Canada
        16.2.1. Pricing Analysis
        16.2.2. Market Share Analysis, 2022
            16.2.2.1. By Vaccine Type
            16.2.2.2. By Valance
            16.2.2.3. By Indication
            16.2.2.4. By Route of Administration
            16.2.2.5. By Distribution Channel
    16.3. Brazil
        16.3.1. Pricing Analysis
        16.3.2. Market Share Analysis, 2022
            16.3.2.1. By Vaccine Type
            16.3.2.2. By Valance
            16.3.2.3. By Indication
            16.3.2.4. By Route of Administration
            16.3.2.5. By Distribution Channel
    16.4. Mexico
        16.4.1. Pricing Analysis
        16.4.2. Market Share Analysis, 2022
            16.4.2.1. By Vaccine Type
            16.4.2.2. By Valance
            16.4.2.3. By Indication
            16.4.2.4. By Route of Administration
            16.4.2.5. By Distribution Channel
    16.5. Germany
        16.5.1. Pricing Analysis
        16.5.2. Market Share Analysis, 2022
            16.5.2.1. By Vaccine Type
            16.5.2.2. By Valance
            16.5.2.3. By Indication
            16.5.2.4. By Route of Administration
            16.5.2.5. By Distribution Channel
    16.6. UK
        16.6.1. Pricing Analysis
        16.6.2. Market Share Analysis, 2022
            16.6.2.1. By Vaccine Type
            16.6.2.2. By Valance
            16.6.2.3. By Indication
            16.6.2.4. By Route of Administration
            16.6.2.5. By Distribution Channel
    16.7. France
        16.7.1. Pricing Analysis
        16.7.2. Market Share Analysis, 2022
            16.7.2.1. By Vaccine Type
            16.7.2.2. By Valance
            16.7.2.3. By Indication
            16.7.2.4. By Route of Administration
            16.7.2.5. By Distribution Channel
    16.8. Spain
        16.8.1. Pricing Analysis
        16.8.2. Market Share Analysis, 2022
            16.8.2.1. By Vaccine Type
            16.8.2.2. By Valance
            16.8.2.3. By Indication
            16.8.2.4. By Route of Administration
            16.8.2.5. By Distribution Channel
    16.9. Italy
        16.9.1. Pricing Analysis
        16.9.2. Market Share Analysis, 2022
            16.9.2.1. By Vaccine Type
            16.9.2.2. By Valance
            16.9.2.3. By Indication
            16.9.2.4. By Route of Administration
            16.9.2.5. By Distribution Channel
    16.10. China
        16.10.1. Pricing Analysis
        16.10.2. Market Share Analysis, 2022
            16.10.2.1. By Vaccine Type
            16.10.2.2. By Valance
            16.10.2.3. By Indication
            16.10.2.4. By Route of Administration
            16.10.2.5. By Distribution Channel
    16.11. India
        16.11.1. Pricing Analysis
        16.11.2. Market Share Analysis, 2022
            16.11.2.1. By Vaccine Type
            16.11.2.2. By Valance
            16.11.2.3. By Indication
            16.11.2.4. By Route of Administration
            16.11.2.5. By Distribution Channel
    16.12. Thailand
        16.12.1. Pricing Analysis
        16.12.2. Market Share Analysis, 2022
            16.12.2.1. By Vaccine Type
            16.12.2.2. By Valance
            16.12.2.3. By Indication
            16.12.2.4. By Route of Administration
            16.12.2.5. By Distribution Channel
    16.13. Singapore
        16.13.1. Pricing Analysis
        16.13.2. Market Share Analysis, 2022
            16.13.2.1. By Vaccine Type
            16.13.2.2. By Valance
            16.13.2.3. By Indication
            16.13.2.4. By Route of Administration
            16.13.2.5. By Distribution Channel
    16.14. Australia
        16.14.1. Pricing Analysis
        16.14.2. Market Share Analysis, 2022
            16.14.2.1. By Vaccine Type
            16.14.2.2. By Valance
            16.14.2.3. By Indication
            16.14.2.4. By Route of Administration
            16.14.2.5. By Distribution Channel
    16.15. GCC Countries
        16.15.1. Pricing Analysis
        16.15.2. Market Share Analysis, 2022
            16.15.2.1. By Vaccine Type
            16.15.2.2. By Valance
            16.15.2.3. By Indication
            16.15.2.4. By Route of Administration
            16.15.2.5. By Distribution Channel
    16.16. South Africa
        16.16.1. Pricing Analysis
        16.16.2. Market Share Analysis, 2022
            16.16.2.1. By Vaccine Type
            16.16.2.2. By Valance
            16.16.2.3. By Indication
            16.16.2.4. By Route of Administration
            16.16.2.5. By Distribution Channel
    16.17. Israel
        16.17.1. Pricing Analysis
        16.17.2. Market Share Analysis, 2022
            16.17.2.1. By Vaccine Type
            16.17.2.2. By Valance
            16.17.2.3. By Indication
            16.17.2.4. By Route of Administration
            16.17.2.5. By Distribution Channel
17. Market Structure Analysis
    17.1. Competition Dashboard
    17.2. Competition Benchmarking
    17.3. Market Share Analysis of Top Players
        17.3.1. By Regional
        17.3.2. By Vaccine Type
        17.3.3. By Valance
        17.3.4. By Indication
        17.3.5. By Route of Administration
        17.3.6. By Distribution Channel
18. Competition Analysis
    18.1. Competition Deep Dive
        18.1.1. Sanofi SA
            18.1.1.1. Overview
            18.1.1.2. Product Portfolio
            18.1.1.3. Profitability by Market Segments
            18.1.1.4. Sales Footprint
            18.1.1.5. Strategy Overview
                18.1.1.5.1. Marketing Strategy
        18.1.2. Merck & Co., Inc
            18.1.2.1. Overview
            18.1.2.2. Product Portfolio
            18.1.2.3. Profitability by Market Segments
            18.1.2.4. Sales Footprint
            18.1.2.5. Strategy Overview
                18.1.2.5.1. Marketing Strategy
        18.1.3. Pfizer BioNTech
            18.1.3.1. Overview
            18.1.3.2. Product Portfolio
            18.1.3.3. Profitability by Market Segments
            18.1.3.4. Sales Footprint
            18.1.3.5. Strategy Overview
                18.1.3.5.1. Marketing Strategy
        18.1.4. CSL Limited
            18.1.4.1. Overview
            18.1.4.2. Product Portfolio
            18.1.4.3. Profitability by Market Segments
            18.1.4.4. Sales Footprint
            18.1.4.5. Strategy Overview
                18.1.4.5.1. Marketing Strategy
        18.1.5. Johnson & Johnson
            18.1.5.1. Overview
            18.1.5.2. Product Portfolio
            18.1.5.3. Profitability by Market Segments
            18.1.5.4. Sales Footprint
            18.1.5.5. Strategy Overview
                18.1.5.5.1. Marketing Strategy
        18.1.6. Emergent Biosolutions Inc.
            18.1.6.1. Overview
            18.1.6.2. Product Portfolio
            18.1.6.3. Profitability by Market Segments
            18.1.6.4. Sales Footprint
            18.1.6.5. Strategy Overview
                18.1.6.5.1. Marketing Strategy
        18.1.7. AstraZeneca plc
            18.1.7.1. Overview
            18.1.7.2. Product Portfolio
            18.1.7.3. Profitability by Market Segments
            18.1.7.4. Sales Footprint
            18.1.7.5. Strategy Overview
                18.1.7.5.1. Marketing Strategy
        18.1.8. Bavarian Nordic A/S
            18.1.8.1. Overview
            18.1.8.2. Product Portfolio
            18.1.8.3. Profitability by Market Segments
            18.1.8.4. Sales Footprint
            18.1.8.5. Strategy Overview
                18.1.8.5.1. Marketing Strategy
        18.1.9. Mitsubishi Tanabe Pharma Corporation
            18.1.9.1. Overview
            18.1.9.2. Product Portfolio
            18.1.9.3. Profitability by Market Segments
            18.1.9.4. Sales Footprint
            18.1.9.5. Strategy Overview
                18.1.9.5.1. Marketing Strategy
        18.1.10. Serum Institute of India Pvt. Ltd.
            18.1.10.1. Overview
            18.1.10.2. Product Portfolio
            18.1.10.3. Profitability by Market Segments
            18.1.10.4. Sales Footprint
            18.1.10.5. Strategy Overview
                18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Recommendations

Healthcare

Meningococcal Vaccine Market

May 2024

REP-GB-1252

312 pages

Healthcare

Anti-Infective Vaccines Market

December 2022

REP-GB-1353

250 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Vaccines Market

Schedule a Call